GTx To File NDA For Acapodene In Early 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III interim analysis finds the selective estrogen receptor modulator lowers cholesterol associated with androgen deprivation therapy for prostate cancer.
You may also be interested in...
GTx Closer To Filing NDA For Acapodene With Promising Phase III Results
Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.
GTx Closer To Filing NDA For Acapodene With Promising Phase III Results
Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.
GTx Phase IIIb Study Will Evaluate Therapy For Prostate Cancer Treatment Side Effects
GTx is initiating an extension of its Phase III clinical trial of Acapodene in prostate cancer patients.